Mode
Text Size
Log in / Sign up
Phase 3 Completed N=68 Treatment

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Source: ClinicalTrials.gov NCT00702715 ↗
Enrolled (actual)
68
Serious AEs
17.7%
Results posted
Apr 2011
Primary outcomePrimary: Time to Recovery of the T4/T1 Ratio to 0.9. — 205; 112 seconds

Summary

The current trial was designed to investigate the effects of 4.0 mg.kg-1 of sugammadex on efficacy, safety and pharmacokinetics in subjects with severe renal impairment in comparison to subjects with normal renal function.

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Recovery of the T4/T1 Ratio to 0.9.
205; 112
SECONDARY
Time to Recovery of the T4/T1 Ratio to 0.8
169; 90
SECONDARY
Time to Recovery of T4/T1 Ratio to 0.7
144; 79

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age
  • ASA class 1-3
  • Creatinine clearance (CLcr) = 80

mL/min (for control group)

-Scheduled for a surgical procedure under general anesthesia with propofol

requiring neuromuscular relaxation with the use of rocuronium

  • Scheduled for a surgical procedure in supine position
  • Written informed consent

Exclusion Criteria

  • Subjects known or suspected to have neuromuscular disorders impairing

neuromuscular blockade and/or significant hepatic dysfunction

  • Subjects scheduled for renal transplant surgery
  • Subjects known or suspected to have a (family) history of malignant

hyperthermia

-Subjects known or suspected to have an allergy to narcotics, muscle

relaxants or other medication used during general anesthesia

  • Subjects receiving fusidic acid, toremifene and/or flucloxacillin
  • Subjects who have already participated in a sugammadex trial
  • Subjects who have participated in another clinical trial, not pre-approved

by the sponsor, within 30 days of entering into 19.4.328 (P05769)

  • Female subjects who are pregnant
  • Female subjects who are breast-feeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00702715). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search